Kimia Biosciences hit an upper circuit limit of 20% at Rs 56 after the company said it has been validated for supplying pharmaceutical raw material (Bilastine) to Bangladesh.
Kimia Biosciences has been recognized/validated for supplying pharmaceutical raw material ('Bilastine') to Bangladesh by Directorate General of Drug Administration & Licensing Authority (Drugs), Govt. of the people's republic of Bangladesh.This certificate of source validation is valid for 3 years from date of issue.
Kimia Biosciences reported net loss of Rs 1.27 crore in Q2 September 2021 as against net profit of Rs 3.61 crore in Q2 September 2020. Net sales declined 17.52% to Rs 30.93 crore in Q2 September 2021 over Q2 September 2020.
Kimia Biosciences is engaged in manufacturing bulk drugs addressing various therapeutic segments and has envisaged growth plans through infrastructure creation and CMS.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app